H ypertension is the leading cause of stroke and cardiovascular diseases and the chief risk factor for global disease burden. With few exceptions, the molecular bases of the most common forms of human hypertension are yet to be defined and, thus, its early diagnosis and clinical management remains challenging, reflecting the complexity of a disease in which multiple environmental and genetic factors contribute to its multifaceted cause. 1 Studies from us and others added 20-hydroxyeicosatetraenoic acid , the product of the ω-hydroxylation of arachidonic acid by cytochrome P450 (CYP) 4A and 4F isozymes, 2 to the list of factors contributing to the pathophysiology of hypertension and its cardiovascular consequences. [3] [4] [5] This is supported by studies identifying associations between variants in the human CYP4A11 and CYP4F2 genes and the prevalence of hypertension, myocardial infarction, and stroke, [6] [7] [8] [9] and clinical studies showing changes in plasma and urinary levels of 20-HETE in hypertension and in diseases and conditions such as cancer, 10 endothelial dysfunction, 11 oxidative stress, 12 obesity and metabolic syndrome, 13, 14 diabetes mellitus, 15 autosomal dominant polycystic kidney disease, 16 and chronic kidney disease. 17, 18 The proposed contributions of 20-HETE to the cause of cardiovascular diseases stem primarily from its reported actions on the vasculature. 20-HETE is a potent vasoactive eicosanoid whose vascular effects include stimulation of smooth muscle contractility, migration, and proliferation, as well as endothelial cell (EC) dysfunction and inflammation. 19, 20 While studying 20-HETE triggered signaling cascades mediating endothelial dysfunction and activation, we identified the phosphorylation of the epidermal growth factor receptor (EGFR) as a first step in a mitogen-activated protein kinase-inhibitor of nuclear factor κ-B kinase subunit β-nuclear factor κB transduction pathway leading to endothelial nitric oxide (NO) synthase uncoupling, inflammatory cytokine production, and to increases in angiotensin-converting enzyme (ACE) expression and activity. [21] [22] [23] [24] Although the mechanisms by which 20-HETE activates EGFR phosphorylation remained unknown, we postulated that 20-HETE could either (1) cross the cell membrane and stimulate tyrosine kinases within the intracellular milieu or (2) interact with a G-proteincoupled receptor (GPCR), the activation of which could lead to transactivation of the EGFR, as was documented for many autacoids including angiotensin II. 25, 26 Interestingly, Akbulut et al 27 showed that 20-HETE activates the Raf/MEK/ERK pathway in renal epithelial cells through an EGFR-and c-Src-dependent mechanism and proposed the presence of a 20-HETE-specific GPCR-EGFR transactivation through c-Src. The presence of a receptor/binding site for 20-HETE was suggested by the development of specific analogs and antagonists that mimic or block many of the known 20-HETE bioactions. 22, 28 With this in mind, we embarked on the challenging task of searching for the 20 
Novelty and Significance
What Is Known?
• 20-hydroxyeicosatetraenoic acid (20-HETE), a bioactive lipid autacoid, plays a role in the pathogenesis of hypertension, stroke, myocardial infarction, renal failure, and diabetes mellitus.
• The actions of 20-HETE seem to involve interaction with a specific receptor/target molecule; yet, the cellular presence of a specific receptor for 20-HETE has not been demonstrated.
What New Information Does This Article Contribute?
• This study identifies G-protein receptor 75 (GPR75), an orphan G-protein-coupled receptor, as the putative 20-HETE-receptor. This is the first time a G-protein-coupled receptor has been identified for an eicosanoid of this class.
• The experimental approach to identifying a specific receptor target for 20-HETE included the use of a click chemistry crosslinking analog, proteomics, protein partner analysis, receptor binding assays, gene silencing, and functional assays.
• 20-HETE binding to GPR75 activates distinct signaling cascades in endothelial and vascular smooth muscle cells that culminate in the activation of vascular angiotensin-converting enzyme expression, endothelial dysfunction, contractility, remodeling, and hypertension.
• The discovery of 20-HETE-GPR75 pairing opens the door for future research with regard to how this lipid-receptor interaction is involved in a variety of pathologies known to be closely mediated and associated with 20-HETE.
The high prevalence and the significant contribution of hypertension to cardiovascular and renal disease comprise its position as the top contributor to the burden of disease worldwide. However, with few exceptions, the molecular basis underlying the pathogenesis of hypertension remains to be defined. Moreover, despite the large number of available treatment options, a significant portion of the hypertensive population has uncontrolled blood pressure. The plethora of available antihypertensive drugs, while lowering blood pressure, do not always correct the organ damage associated with hypertension. 20-HETE has been identified as a significant contributing factor to the pathophysiology of hypertension and its cardiovascular consequences. In this study, we identified a cell surface receptor, the orphan G-protein-coupled receptor (Gq) GPR75, to which 20-HETE binds to and initiates a cell-signaling cascade leading to endothelial cell dysfunction and vascular smooth muscle contractility. This study further show that knockdown of GPR75 prevents 20-HETE-mediated vascular remodeling and hypertension. The identification of 20-HETE-GPR75 pairing opens the door for discovery, and there is much to be explored including the role of this interaction in a variety of diseases/pathologies associated with 20-HETE (eg, stroke and myocardial infarction). 29 Male Cyp4a12tg mice (8-to 14-week-old) were used in all experiments. Mice were maintained on a 12-hour light/dark cycle and fed ad libitum. doxycycline (1 mg/mL) was administered in the drinking water. In some experiments, Cyp4a12tg mice were anesthetized under isoflurane and administered lentiviral constructs via a single retro-orbital injection to maximize systemic distribution. Each mouse was injected with 100 µL of either 4.33×10 9 TU/mL of nontargeting or 7.29×10 9 TU/mL of GPR75-targeted shRNA particles. The administration of doxycycline (1 mg/mL) was initiated 48 hours after the lentiviral injection. Blood pressure was monitored by radiotelemetry and tail cuff before and after administration of doxycycline for 14 to 35 days. At the end of all experiments, mice were anesthetized and laporotomy was performed. Renal preglomerular arteries (the whole circulatory tree) or interlobar arteries (80-100 µm) were microdissected and collected for Western blot analysis and functional studies. All results are expressed as mean±SEM. Significance of difference in mean values was determined using t test and 1-way ANOVA, followed by the Newman-Keul post hoc test. P<0.05 was considered to be significant.
Results

Identification of GPR75-20-HETE Pairing
We synthesized an analog of 20-HETE, 20- Figure 1A ) that contained both benzophenone, a photoreactive crosslinker for protein binding, and an azide, for selective binding and labeling to a click-chemistry dibenzocyclooctyne 800CW Infrared Dye. 20-APheDa functions as a 20-HETE antagonist as inferred from its ability to block 20-HETE-mediated sensitization of phenylephrine vasoconstriction by decreasing (4-fold) the EC 50 ( Figure 1B) . Incubation of 10 nmol/L of 20-APheDa with membrane fractions of human EC (20 μg) followed by 15 minutes of UV (365 nm) crosslinking and 1 hour of incubation with the click reagent (dibenzocyclooctyne-IRdye 800CW, LiCor; 50 µmol/L) yielded several bands, including a dominant band located at 47 to 49 kDa ( Figure 1C ). This labeling profile of several bands is characteristic of many click-chemistry interactions whereby multiple proteins in close proximity to the binding site of the compound, in this case 20-APheda, are labeled. 30 Nevertheless, the labeling of these bands by 20-APheDa (0.1 nmol/L) was competed by excess amounts of 20-HETE (100 μmol/L), but not of 12-hydroxyeicosatetraenoic acid (100 μmol/L; Figure 1D and 1E).
In-gel 20-APheDa-protein complexes were extracted from independent incubations and protein identified by Applied Biomics (Hayward, CA). Protein identification of the dominant band location was based on peptide fingerprint mass mapping (using MS data) and peptide fragmentation mapping (using MS/ MS data). The MASCOT search engine was used to identify proteins from primary sequence databases. Analysis of sequenced samples from the dominant band location identified several proteins and domains as top hits including TGFB1I1 or hydrogen peroxide-inducible clone 5 (HIC-5), 31 POTE ankyrin domain family members, Zinc finger proteins, and GTP-binding proteins as top hits (Online Figure I ). Further analysis also suggested domains and proteins associated with G-protein-coupled receptor kinase interactor 1 (GIT1), a GPCR-kinase-interacting protein-1 scaffold protein with ADP-ribosylating factor GTPase activity providing clues toward the possibility of a multiprotein receptor complex in close proximity to 20-APheDa's binding site. 32 With the identification of these 2 particular proteins, we utilized protein partner analysis against orphan Gq Class A receptors referencing STRING (protein-protein interaction networks STRING [String-db.org]) and NCBI (National Center for Biotechnology Information) protein partner databases. The analysis revealed an association of HIC-5 and GIT1 with a candidate orphan receptor GPR75. To this end, in 1 of 3 separate experiments GPR75-specific sequences were detected with CI of 99.045%, based on peptide fingerprint mass and fragmentation mapping using the MASCOT search engine, encouraging further investigation as to a potential relationship between 20-HETE and GPR75. Moreover, databases including the Human Protein Atlas, BioGPS, and GeneAtlas demonstrate tissue-specific expression of Gpr75 to be broadly distributed across various organs including the brain, endocrine tissues, lung, kidney, heart, adipose tissues, aorta, and other tissues. Our assessment of Gpr75 expression in tissues from C57BL/6 mice by quantitative polymerase chain reaction (qPCR) concurred with the distribution profile presented in these databases (Online Figure II) . Many of these tissues are heavily vascularized and have the capacity to produce 20-HETE.
Analyses of competition binding studies were performed. As seen in Figure 2A 
GPR75 Is Expressed in the Vascular Endothelium and Is Associated With Gα q/11 , GIT1, and HIC-5
Antibodies against the GPR75 C-terminal, which recognize a single 54-to 55-kDa protein band (Online Figure III) , were used in all subsequent experiments. A representative image of kidney sections costained with antibodies against GPR75 and CD31, an EC marker, showed a clear colocalization of GPR75 to the vascular endothelium and expression of GPR75 can be observed throughout the vessel ( Figure 3A) . Moreover, immunoprecipitation and immunoblotting experiments indicated that Gα q/11 as well as GIT1 and HIC-5 are associated with GPR75 in EC ( Figure 3B ).
20-HETE Alters the Association of GPR75 With Gα q/11 , GIT1, and HIC-5 in Endothelial Cells
Incubation of EC with 20-HETE (5 minutes) decreased GPR75-Gα q/11 association by 44% and 51% at 1 and 10 nmol/L ( Figure 3C ). In addition, 20-HETE also increased GPR75-GIT1 binding by 2-fold and HIC-5-GPR75 dissociation by 60% ( Figure 3D and 3E) . Importantly, 20-6,15-HEDGE, an effective 20-HETE antagonist in vitro and in vivo, 29, 33 did not increase GIT1-GPR75 association. Moreover, it prevented 20-HETE-stimulated GIT1-GPR75 association ( Figure 3F ).
GPR75 and GIT1 Are Required for 20-HETEMediated EGFR Phosphorylation and Downstream Signaling
Previously, we documented that phosphorylation of EGFR is an early step in 20-HETE-mediated activation of a mitogenactivated protein kinase-inhibitor of nuclear factor κ-B kinase subunit β-nuclear factor κB signaling leading to endothelial NO synthase uncoupling, ACE induction, and inflammatory cytokine production in EC. 22, 24, 34 To investigate the role of GPR75 and GIT1 in 20-HETE-mediated phosphorylation of EGFR, small interfering RNAs (siRNA) against GPR75 and GIT1 were used. Transfection of EC with siRNAs against GPR75 and GIT1 produced a maximal knockdown of 85% and 70%, respectively ( Figure 4A and 4B) . As shown previously, 20-HETE increases total tyrosine phosphorylation of immunoprecipitated EGFR in EC transduced with control siRNA by 1.99±0.16-fold ( Figure 4C ). 20-HETE-stimulated EGFR tyrosine phosphorylation was completely prevented in EC transduced with either GPR75 or GIT1 siRNA ( Figure 4C ). In addition, within the same time frame in which 20-HETE stimulated a 2.3-fold increase in EGFR phosphorylation ( Figure 4D ), it also decreased the association of c-Src with GIT1 by 72% ( Figure 4E ) and increased association of c-Src with EGFR by 110% ( Figure 4F ), suggesting that 20-HETE binding to GPR75 activates a c-SRC-mediated EGFR phosphorylation via GIT1.
20-HETE-Mediated Induction of ACE mRNA Requires GPR75
One of the most prominent effects of 20-HETE in the vascular endothelium is induction of ACE transcription and activity. 22, 24 Here, we show that suppression of GPR75 in EC by GPR75-specific siRNAs negated the 3.4-fold induction of ACE mRNA by 20-HETE ( Figure 4G ), indicating that GPR75-20-HETE pairing is a necessary step for 20-HETE-mediated induction of ACE. Importantly, the chemokine CCL5, a proposed GPR75 ligand, 35 did not induce ACE transcription nor did it increase EGFR tyrosine phosphorylation or Gα q/11 -GPR75 association in EC (Online Figure IV) .
GPR75 Knockdown Prevents 20-HETE-Dependent Hypertension, Vascular Dysfunction, and Remodeling
The Cyp4a12 transgenic mice (Cyp4a12tg) in which the expression of the Cyp4a12-20-HETE synthase is under the control of doxycycline display, on administration of doxycycline, increased levels of 20-HETE that is associated with vascular dysfunction and hypertension, both of which are prevented or reversed by inhibiting the biosynthesis or blocking the actions of 20-HETE. 29, 33 We used this model to assess whether GPR75 is necessary for the prohypertensive actions of 20-HETE. Mice were given a bolus injection of either control or GPR75-targeted shRNA lentiviral particles into the retroorbital sinus followed by administration of doxycycline in the drinking water to induce Cyp4a12-20-HETE synthase. As expected, administration of doxycycline to Cyp4a12tg mice that received a bolus of control shRNA lentiviral particles or its vehicle resulted in a rapid and sustained increase in systolic blood pressure measured by the tail cuff method (135±2 and 131±3 mm Hg, respectively; Figure 5A and 5B). In contrast, doxycycline administration to Cyp4a12tg mice that received a bolus of GPR75-targeted shRNA failed to increase blood pressure (110±2 mm Hg; tail cuff, Figure 5A and 5B and telemetry; Online Figure V) . Western blot analysis of renal preglomerular microvessels from mice receiving GPR75-targeted shRNA lentiviral particles confirmed an 80% knockdown of GPR75 levels ( Figure 5C ). Similar reduction in GPR75 expression was seen in other tissues, including the liver (45%) and heart (80%; Online Figure VI) . Elevated vascular ACE has been characterized as a hallmark of the doxycycline-induced 20-HETE-dependent hypertension in Cyp4a12tg mice. 33 In line with previous studies, vascular ACE expression in doxycycline-and doxycycline+control shRNA-treated Cyp4a12tg mice increased by 3.3-and 3.8-fold, respectively ( Figure 5D ). In contrast, vascular ACE expression was not induced in doxycycline-treated Cyp4a12tg mice that received GPR75-targeted shRNA lentiviral particles ( Figure 5D ), further substantiating the notion that the GPR75-20-HETE pairing is critical to achieve 20-HETEmediated induction of ACE.
The hypertensive phenotype of the doxycycline-treated Cyp4a12tg mice is associated with 20-HETE-dependent endothelial dysfunction and enhanced sensitivity to constrictor stimuli. 29, 33 Here, we show that knockdown of GPR75 interferes with the ability of doxycycline to impair relaxations to acetylcholine and increase contractions to phenylephrine. The relaxation to acetylcholine was markedly reduced in interlobar arteries from doxycycline-treated (55±3%) when compared with arteries from water-treated Cyp4a12tg mice (99±2%). Administration of GPR75-targeted, but not control, shRNA lentiviral particles prevented doxycycline-induced impairment in relaxation to acetylcholine (88%±3%; Figure 6A ). Likewise, administration of GPR75-targeted shRNA prevented the doxycycline-induced increases in contractions to phenylephrine. Treatment with doxycycline increased sensitivity to phenylephrine (P<0.05) as evidenced by a reduction in EC 50 (from 0.75±011 to 0.40±0.08 µmol/L) and an increase in R max (from 4.89±0.51 to 6.17±0.39 mN/mm) when compared with water-treated Cyp4a12tg mice ( Figure 6B ). However, the EC 50 to phenylephrine in arteries from doxycycline-treated mice that received GPR75-targeted shRNA was unchanged (0.86±0.24 µmol/L) and was not different from the EC 50 in arteries from control mice ( Figure 6B) .
Remodeling of the renal microvasculature is a striking pathology associated with chronic hypertension. Prolonged exposure of the vasculature to high levels of 20-HETE as in the androgen-treated rats or Cyp4a12tg mice receiving doxycycline leads to hypertrophic remodeling of the renal microvessels in a 20-HETE-dependent manner that is largely independent of blood pressure elevation. 33, 36 In this study, assessment of remodeling in interlobar arteries (≈80-100 µm) showed that hypertension in Cyp4a12tg mice receiving control shRNA+doxycycline for 35 days was associated with a 3-fold increase in media thickness, media:lumen ratio, and cross-sectional area ( Figure 6C through 6F ). In contrast, neither hypertension nor microvascular remodeling occurred in arteries from doxycycline-treated Cyp4a12tg mice that received GPR75-targeted shRNA ( Figure 6C through 6F). Taken together, these data strongly support the notion that activation of GPR75 is a necessary step in 20-HETE-mediated hypertension, endothelial dysfunction, vascular smooth muscle contractions, and microvascular remodeling. entry through the L-type Ca 2+ channels. 37 As seen in Figure 7 , GPR75 is expressed in cultured aortic vascular smooth muscle cells. In these cells, 20-HETE stimulated the dissociation of Gα q/11 from GPR75 ( Figure 7A ), GPR75-GIT1 association ( Figure 7B ), GIT1-protein kinase Cα dissociation ( Figure 7C ), protein kinase Cα-large conductance voltage and calcium-activated potassium subunit β association ( Figure 7D ), c-Src-large conductance voltage and calciumactivated potassium subunit β association ( Figure 7E) , and large conductance voltage and calcium-activated potassium subunit β tyrosine phosphorylation ( Figure 7F ). The phosphorylation of the large conductance voltage and calciumactivated potassium subunit β subunit of the BK ca channels leads to the inactivation of the channel and consequently to vasoconstriction.
20-HETE-GPR75 Pairing in Vascular Smooth
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Discussion
Recent clinical studies and findings in animal models of genetically determined dysfunction identified 20-HETE as a key lipid regulator of vascular, renal, and cardiac functions. Numerous reports documented causal relationships and polymorphic associations between levels of 20-HETE and its biosynthetic enzymes with hypertension, vascular and renal injury, and cardiac hypertrophy. 5 The discovery of a receptorligand interaction between 20-HETE and the GPR75 orphan receptor, capable of modulating some of the published effects of 20-HETE in the regulation of vascular function and blood pressure, represents a major breakthrough in this area of research; it provides the molecular basis for the signaling and pathophysiological functions mediated by 20-HETE and is the first identification of a CYOP450-derived eicosanoid receptor.
The presence of a specific cellular receptor/target for 20-HETE has been contemplated since the first demonstration of its occurrence within the renal and cerebral microcirculation and its distinctive roles in the regulation of the myogenic tone. The identification of a specific receptor, responsible for the bioactive properties of 20-HETE, posed significant difficulties as 20-HETE is chemically and metabolically labile and, as a lipid, it can cross membranes, and is rapidly esterified into phospholipids, or effectively binds/sticks to proteins. To overcome some of these difficulties, we used the 20-HETE analog, 20-APheDa, and click chemistry methodology coupled with protein partner identification to expose a multiprotein complex that is associated with 20-HETE binding in EC. The use of 20-APheDa allowed us to take on a broader approach and obtain clues toward identifying receptor candidates. Click-chemistry compounds have been proven to be useful for labeling and used for the identification of multiprotein complexes and interactions. 30 In these experiments, we aimed at potentially labeling several proteins in close proximity to 20-APheDa in its bound and docked position. Several in-gel 20-APheDa-protein complexes were observed including a dominant band, which became the focus of our analysis. This band revealed 20-APheDa's effective labeling of several proteins, and it was not until this information was used for protein partner analysis that we were able to identify a candidate receptor GPR75, a member of the rhodopsin Gq receptor family, as the putative GPCR. The ligand-receptor pairing of 20-HETE with GPR75 was further demonstrated by competition binding studies in EC membranes leading to Kd values that are well within the concentration range of 20-HETE biological actions. Moreover, the finding that GPR75-deficient EC do not bind 20-HETE clearly support the hypothesis that GPR75 is the receptor target for 20-HETE in these cells. In line with the fact that GPR75 is a Gα q/11 -coupled receptor are the demonstrations that 20-HETE increases IP-1 accumulation, an effect not present in GPR75-deficient cells, and that 20-HETE rapidly dissociates Gα q/11 from GPR75. All together, these results indicate that 20-HETE binds to EC membranes, pairs with GPR75, and functionally activates it.
In 1999, Tarttelin et al 39 identified GPR75 as a novel human GPCR that maps to chromosome 2p16 and encodes a 540 amino acid protein. Initial findings showed GPR75 to be predominantly expressed in cells surrounding retinal arterioles and in other areas of the brain. 39, 40 Numerous databases indicated a broad expression profile for Gpr5 in the majority of human tissues, and our qPCR assessment in tissues from C57BL/6 corroborated this expression profile. Ignatov et al 35 reported that the chemokine CCL5 increased IP 3 and intracellular Ca 2+ in CHO (Chinese hamster ovary) or HEK (human embryonic kidney) cells overexpressing the mouse GPR75 via a Gq-protein-coupled phospholipase C (PLC)-mediated signal transduction. No direct binding studies were documented in that study. A recent study by Liu et al 41 showed that CCL5 stimulates insulin secretion in isolated islets via PLC-activated Ca 2+ influx in a GPR75-dependent manner; however, they also did not document direct binding or interaction between GPR75 and CCL5. Importantly, the pairing of CCL5 and GPR75 could not be repeated in a recent β-arrestin assay and the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification still classifies GPR75 as an orphan receptor. 42, 43 Notably, in our hands, CCL5 failed to dissociate Gα q/11 from GPR75 in EC. Moreover, CCL5 lacked the ability to transactivate EGFR We proposed GPR75 as a 20-HETE receptor based on 2 key original findings. First, when applied to EC, 20-HETE binds and activates the receptor at a concentration that elicits a specific EGFR-mitogen-activated protein kinase-inhibitor of nuclear factor κ-B kinase subunit β-nuclear factor κB signaling pathway to induce ACE transcription, uncouple endothelial NO synthase, and stimulate cytokine production. 22, 24, 34, 44 This activation involves dissociation of Gα q/11 from GPR75 and increased GIT1-GPR75 association followed by c-Srcmediated 20-HETE-dependent EGFR phosphorylation, the first step of 20-HETE signaling in EC. Moreover, both GPR75 and GIT1 are required not only for 20-HETE-mediated transactivation of EGFR but also for the downstream effect of 20-HETE to induce ACE in EC (Figure 8 ). The dissociation of Gα q/11 from GPR75 after the addition of 20-HETE, most likely, initiated a PLC-IP-3-mediated increases in [Ca 2+ ], a common signaling pathway for Gq-coupled receptor. Hence, the demonstration that 20-HETE increases IP-1 levels in a GPR75-dependent manner further indicates a functional GPR75-20-HETE pairing. In smooth muscle cells, inhibition of the BK ca channels underlies 20-HETE-mediated vasoconstriction. 45 Here, we link GPR75-20-HETE pairing to stimulation of Gα q/11 dissociation and GIT1-mediated protein kinase Cα-and cSrc-stimulated tyrosine phosphorylation of large conductance voltage and calcium-activated potassium subunit β, which inactivates the channel 38, 46 and alters BK ca subunit trafficking 47 leading to cell depolarization, elevation in cytosolic [Ca 2+ ], and stimulation of the contractile apparatus. The role of HIC-5 in the vascular endothelium is unclear. HIC-5 has been shown to interact with GIT1 48 and coactivates the androgen receptor. 49 The interaction between HIC-5 and the androgen receptor may account for the strong relationship between androgens and 20-HETE. 50 The second key finding in this study is that the expression of GPR75 is required for the 20-HETE prohypertensive activities. The conditional Cyp4a12tg mice display doxycycline-mediated hypertension along with vascular dysfunction and remodeling in a 20-HETE-dependent manner. 29, 33 20-HETE-mediated vascular dysfunction and remodeling has been shown to be largely independent of blood pressure elevation. 33, 36 We hypothesized that if GPR75 is the 20-HETE receptor; its disruption should prevent hypertension in the doxycycline-treated Cyp4a12tg mice. Indeed, knockdown of GPR75 in doxycycline-treated Cyp4a12tg mice prevented the 20-HETE-dependent hypertension along with marked reduction in endothelial dysfunction, smooth muscle contractility, and vascular remodeling. These results clearly place GPR75 as a novel target in the control of blood pressure and vascular function. Until recently, there were no observed associations between GPR75 and hypertension. There is, however, a report that identified GPR75 among other potential candidate genes in a locus on chromosome 2p, which shows significant linkage to antihypertensive responses in the British Genetics of Hypertension Study. 51 As indicated above, GPR75 has been shown to express in a wide variety of tissues including the brain, heart, and kidney. All of these tissues participate in blood pressure control and have been shown to have the capacity to produce 20-HETE. Accordingly, one may expect the presence of 20-HETE-GPR75 pairing in these tissues that may also contribute to hypertension. To this end, we found that GPR75 is also expressed along the nephron, primarily on the luminal side of the proximal tubules (unpublished data) where 20-HETE is presumably activating the NHE3 via angiotensin II-dependent mechanisms. 52 Interestingly, salt-sensitive hypertension in mice expressing the human CYP4A11-20-HETE synthase was attributed to enhanced Na retention resulting from 20-HETE-and Ang II-dependent NCC upregulation. 53 Salt-sensitive hypertension was also shown in rats with depressed renal medullary 20-HETE synthesis, which conditions Na retention in the ascending limb of the loop of Henle. [54] [55] [56] [57] Inasmuch as 20-HETE contributes to prohypertensive mechanisms via vascular and tubular actions that foster vasoconstriction and conservation of sodium, and to antihypertensive mechanisms via actions that facilitate Na excretion, it is expected that the blood pressure effect of interventions that interfere with 20-HETE actions is conditioned by both mechanisms. The discovery of 20-HETE-GPR75 pairing provides a unique opportunity to confront the seemingly opposing actions of 20-HETE on blood pressure and explore the contribution of GPR75-20-HETE interactions in other tissues, including the central nervous system, to hypertension.
In summary, we provide strong evidence for a 20-HETE-GPR75 pairing in the vascular endothelium. We also present substantial data demonstrating that GPR75 is a critical Figure 8 . Proposed 20-hydroxyeicosatetraenoic acid (HETE)-G-protein receptor 75 (GPR75)-mediated signaling in endothelial cells. 20-HETE-GPR75 pairing stimulates the dissociation of Gα q/11 and the association of G-protein-coupled receptor-kinase interacting protein-1 (GIT1) to the receptor. The latter facilitates c-Src-mediated endothelial growth factor receptor (EGFR) transactivation. The 20-HETE-GPR75-mediated activation of EGFR results in the stimulation of downstream cascades that regulate vascular angiotensinconverting enzyme (ACE) expression and decreases in nitric oxide (NO) bioavailability. DAG indicates diacylglycerol; eNOS, endothelial nitric oxide synthase; HIC-5, hydrogen peroxide-inducible clone 5; HSP, heat shock protein; IKK, inhibitor of nuclear factor κ-B kinase subunit β; IP, inositol phosphate; NF, nuclear factor; PKC, protein kinase C; and PLC, phospholipase C. component of 20-HETE's signaling and bioactions in vitro and in vivo, regulating vascular tone, and function. This finding opens the door for discovery, and there is much to be explored including the role of this pairing in other sites and organs such as the nervous, endocrine, and respiratory systems. It has the potential to be a game changer in the field of CYP eicosanoids by providing novel targets for the development of new therapies for myriad diseases/pathologies associated with 20-HETE (eg, stroke and myocardial infarction), whereas genetic studies of receptor variants could lead to a better understanding of some discrepancies between 20-HETE levels and reported pro-or antihypertensive properties.
